Advertisement

Medical Treatment Including Kampo Medicine

  • Minoru YagiEmail author
  • Suguru Fukahori
Chapter

Abstract

The surgeons should perform careful assessment and diagnostic plan and are able to improve the quality of life of the patients with HD who are not doing well after operations. In assessing the soiling postoperative patient with HD, it is important to discuss whether the colon of the patient is spastic or dilated. Examination under anesthesia to determine the integrity of the anal canal and status of the sphincters is important and adjusts the patient’s expectations concerning long-term functional result and helps determine what kinds of medical treatment including enema are administrated. In case of anal canal and sphincters intact with hypomotility (atonic constipation), it is necessary to administrate laxatives including prokinetics and Kampo medicine (Juncho-to, Daiokanzo-to, Choi-joki-to containing powdered Rhubarb) for constipation in addition to probiotics. In another case of anal canal and sphincters intact with hypermotility (spastic frequent loose stool), it is suitable to administrate calcium polycarbophil and Kampo medicine Shokentyu-to including Paeoniae radix, in addition to probiotics. Successful management depends on the appropriate evaluation and medical treatment and leads to clean and dry around the neo-anorectal lesion.

Keywords

Fecal incontinence Constipation Laxatives Prokinetics Probiotics Kampo medicine 

References

  1. 1.
    Swenson O, Bill AH. Resection of the rectum and rectosigmoid with preservation of the sphincter for benign spastic lesions producing megacolon. Surgery. 1948;24:212–20.PubMedGoogle Scholar
  2. 2.
    Soave F. A new surgical technique for treatment of Hirschsprung’s disease. Surgery. 1964;56:1007–14.PubMedGoogle Scholar
  3. 3.
    Duhamel B. A new operation for the treatment of Hirschsprung’s disease. Arch Dis Child. 1960;35:38–9.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Rehbein F, Von Zimmermann H. Results with abdominal resection in Hirschsprung’s disease. Arch Dis Child. 1960;35:29–37.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    So HB, Schwartz DL, Becker JM, Daum F, Schneider KM. Endorectal “pull-through” without preliminary colostomy in neonates with Hirschsprung’s disease. J Pediatr Surg. 1980;15:470–1.CrossRefPubMedGoogle Scholar
  6. 6.
    De la Torre-Mondragón L, Ortega-Salgado JA. Transanal endorectal pull-through for Hirschsprung’s disease. J Pediatr Surg. 1998;33:1283–6.CrossRefPubMedGoogle Scholar
  7. 7.
    Langer JC, Durrant AC, de la Torre L, Teitelbaum DH, Minkes RK, Caty MG, Wildhaber BE, Ortega SJ, Hirose S, Albanese CT. One-stage transanal Soave pullthrough for Hirschsprung disease: A multicenter experience with 141 children. Ann Surg. 2003;238:569–83.PubMedPubMedCentralGoogle Scholar
  8. 8.
    Yanchar NL, Soucy P. Long-term outcome after Hirschsprung’s disease: Patients’ perspectives. J Pediatr Surg. 1999;34:1152–60.CrossRefPubMedGoogle Scholar
  9. 9.
    Engum SA, Grosfeld JL. Long-term results of treatment of Hirschsprung’s disease. Semin Pediatr Surg. 2004;13:273–85.CrossRefPubMedGoogle Scholar
  10. 10.
    Rintala RJ, Pakarinen MP. Outcome of anorectal malformations and Hirschsprung’s disease beyond childhood. Semin Pediatr Surg. 2010;19:160–7.CrossRefPubMedGoogle Scholar
  11. 11.
    Levitt MA, Dickie B, Peña A. Evaluation and treatment of the patient with Hirschsprung disease who is not doing well after a pull-through procedure. Semin Pediatr Surg. 2010;19:146–53.CrossRefPubMedGoogle Scholar
  12. 12.
    Levitt MA, Peña A. Update on pediatric faecal incontinence. Eur J Pediatr Surg. 2009;19:1–9.CrossRefPubMedGoogle Scholar
  13. 13.
    Levitt MA, Peña A. Pediatric fecal incontinence: A surgeon’s perspective. Pediatr Rev. 2010;31:91–101.CrossRefPubMedGoogle Scholar
  14. 14.
    Levitt MA, Dickie B, Peña A. The Hirschsprungs patient who is soiling after what was considered a “successful” pull-through. Semin Pediatr Surg. 2012;21:344–53.CrossRefPubMedGoogle Scholar
  15. 15.
    Bischoff A, Levitt MA, Bauer C, et al. Treatment of fecal incontinence with a comprehensive bowel management program. J Pediatr Surg. 2009;44:1278–84.CrossRefPubMedGoogle Scholar
  16. 16.
    Levitt MA, Martin CA, Olesevich M, Bauer CL, Jackson LE, Peña A. Hirschsprung disease and fecal incontinence: Diagnostic and management strategies. J Pediatr Surg. 2009;44:271–7.CrossRefPubMedGoogle Scholar
  17. 17.
    Peña A, Elicevik M, Levitt MA. Reoperations in Hirschsprung disease. J Pediatr Surg. 2007;42:1008–14.CrossRefPubMedGoogle Scholar
  18. 18.
    Hashizume N, Yagi M, Ushijima K, Seki Y, Fukahori S, Muto M, Matsufuji H, Taguchi T. Pharmacotherapy for pediatric chronic intestinal pseudo-obstruction: Nationwide survey in Japan. Pediatr Int. 2017;59:467–72.CrossRefPubMedGoogle Scholar
  19. 19.
    Hoy SM, Scott LJ, Wagstaff AJ. Sodium picosulfate/magnesium citrate: a review of its use as a colorectal cleanser. Drugs. 2009;69:123–36.CrossRefPubMedGoogle Scholar
  20. 20.
    Ohkubo H, Iida H, Takahashi H, Yamada E, Sakai E, Higurashi T, Sekino Y, Endo H, Sakamoto Y, Inamori M, Sato H, Fujimoto K, Nakajima A. An epidemiologic survey of chronic intestinal pseudo-obstruction and evaluation of the newly proposed diagnostic criteria. Digestion. 2012;86:12–9.CrossRefPubMedGoogle Scholar
  21. 21.
    Vargas JH, Sachs P, Ament ME. Chronic intestinal pseudoobstruction syndrome in pediatrics. Results of a national survey by members of the North American Society of Pediatric Gastroenterology and Nutrition J Pediatr Gastroenterol Nutr. 1988;7:323–32.PubMedGoogle Scholar
  22. 22.
    Camilleri M, Balm RK, Zinsmeister AR. Symptomatic improvement with one-year cisapride treatment in neuropathic chronic intestinal dysmotility. Aliment Pharmacol Ther. 1996;10:403–9.CrossRefPubMedGoogle Scholar
  23. 23.
    Camilleri M, Malagelada JR, Abell TL, Brown ML, Hench V, Zinsmeister AR. Effect of six weeks of treatment with cisapride in gastroparesis and intestinal pseudoobstruction. Gastroenterology. 1989;96:704–12.PubMedGoogle Scholar
  24. 24.
    Hiyama T, Yoshihara M, Matsuo K, Kusunoki H, Kamada T, Ito M, Tanaka S, Chayama K, Haruma K. Treatment of functional dyspepsia with serotonin agonists: a meta-analysis of randomized controlled trials. J Gastroenterol Hepatol. 2007;22:1566–70.CrossRefPubMedGoogle Scholar
  25. 25.
    Peeters T, Matthijs G, Depoortere I, Cachet T, Hoogmartens J, Vantrappen G. Erythromycin is a motilin receptor agonist. Am J Phys. 1989;257:470–4.CrossRefGoogle Scholar
  26. 26.
    Emmanuel AV, Shand AG, Kamm MA. Erythromycin for the treatment of chronic intestinal pseudo-obstruction: description of six cases with a positive response. Aliment Pharmacol Ther. 2004;19:687–94.CrossRefPubMedGoogle Scholar
  27. 27.
    Akamaru Y, Takahashi T, Nishida T, Omori T, Nishikawa K, Mikata S, Yamamura N, Miyazaki S, Noro H, Takiguchi S, Mori M, Doki Y. Effects of daikenchuto, a Japanese herb, on intestinal motility after total gastrectomy: a prospective randomized trial. J Gastrointest Surg. 2015;19:467–72.CrossRefPubMedGoogle Scholar
  28. 28.
    Katsuno H, Maeda K, Kaiho T, Kunieda K, Funahashi K, Sakamoto J, Kono T, Hasegawa H, Furukawa Y, Imazu Y. Clinical efficacy of Daikenchuto for gastrointestinal dysfunction following colon surgery: a randomized, double-blind, multicenter, placebo controlled study (JFMC39-0902). Jpn J Clin Oncol. 2015;45:650–6.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Uehara S, Ogawa K, Arimitsu J, Okuyama H. “Ninjinto” (ginseng decoction), a traditional Japanese herbal medicine, improves gastrointestinal symptoms and immune competence in patients with chronic intestinal failure. Evid Based Complement Alternat Med. 2015;2015:462586.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Tokita Y, Yuzurihara M, Sakaguchi M, Satoh K, Kase Y. The pharmacological effects of Daikenchuto, a traditional herbal medicine, on delayed gastrointestinal transit in rat postoperative ileus. J Pharmacol Sci. 2007;104:303–10.CrossRefPubMedGoogle Scholar
  31. 31.
    Shibata C, Sasaki I, Naito H, Ueno T, Matsuno S. The herbal medicine Dai-Kenchu-Tou stimulates upper gut motility through cholinergic and 5-hydroxytryptamine 3 receptors in conscious dogs. Surgery. 1999;126:918–24.CrossRefPubMedGoogle Scholar
  32. 32.
    Fukuda H, Chen C, Mantyh C, Ludwig K, Pappas TN, Takahashi T. The herbal medicine, Dai-Kenchu-to, accelerates delayed gastrointestinal transit after the operation in rats. J Surg Res. 2006;131:290–5.CrossRefPubMedGoogle Scholar
  33. 33.
    Iwai N, Kume Y, Kimura O, Ono S, Aoi S, Tsuda T. Effects of herbal medicine Dai-Kenchu-to on anorectal function in children with severe constipation. Eur J Pediatr Surg. 2007;17:115–8.CrossRefPubMedGoogle Scholar
  34. 34.
    Takagi A, Yagi M, Tanaka Y, Asagiri K, Asakawa T, Tanaka H, Ishii S, Egami H, Akaiwa M, Tsuru T. The herbal medicine daikenchuto ameliorates an impaired anorectal motor activity in postoperative pediatric patients with an anorectal malformation: a pilot study. Int Surg. 2010;95:350–5.PubMedGoogle Scholar
  35. 35.
    Fuller R. Probiotics in man and animals. J Appl Bacteriol. 1989;66:365–78.CrossRefPubMedGoogle Scholar
  36. 36.
    Pironi L, Arends J, Bozzetti F, Cuerda C, Gillanders L, Jeppesen PB, Joly F, Kelly D, Lal S, Staun M, Szczepanek K, Van Gossum A, Wanten G, Schneider SM. Home Artificial Nutrition & Chronic Intestinal Failure Special Interest Group of ESPEN: ESPEN guidelines on chronic intestinal failure in adults. Clin Nutr. 2016;35:247–307.CrossRefPubMedGoogle Scholar
  37. 37.
    Bu LN, Chang MH, Ni YH, Chen HL, Cheng CC. Lactobacillus casei rhamnosus Lcr35 in children with chronic constipation. Pediatr Int. 2007;49:485–90.CrossRefPubMedGoogle Scholar
  38. 38.
    Korterink JJ, Ockeloen L, Benninga MA, Tabbers MM, Hilbink M, Deckers-Kocken JM. Probiotics for childhood functional gastrointestinal disorders: A systematic review and meta-analysis. Acta Paediatr. 2014;103:365–72.CrossRefPubMedGoogle Scholar
  39. 39.
    Tabbers MM, Benninga MA. Constipation in children: fibre and probiotics. BMJ Clin Evid. 2015;2015:0303.PubMedPubMedCentralGoogle Scholar
  40. 40.
    Kanamori Y, Kitano Y, Hashizume K, Sugiyama M, Tomonaga T, Takayasu H, Egami S, Goishi K, Shibuya K, Kawana Y, Marumo G, Kikuchi A, Kozuma S, Taketani Y, Sekiyama Y. A case of laryngeal atresia (congenital high airway obstruction syndrome) with chromosome 5p deletion syndrome rescued by ex utero intrapartum treatment. J Pediatr Surg. 2004;39:E25–8.CrossRefPubMedGoogle Scholar
  41. 41.
    Wang X, Li Z, Xu Z, Wang Z, Feng J. Probiotics prevent Hirschsprung’s disease-associated enterocolitis: a prospective multicenter randomized controlled trial. Int J Color Dis. 2015;30:105–10.CrossRefGoogle Scholar
  42. 42.
    Didari T, Mozaffari S, Nikfar S, Abdollahi M. Effectiveness of probiotics in irritable bowel syndrome: updated systematic review with meta-analysis. World J Gastroenterol. 2015;21:3072–84.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Chiba T, Kudara N, Sato M, Chishima R, Abiko Y, Inomata M, Orii S, Suzuki K. Colonic transit, bowel movements, stool form, and abdominal pain in irritable bowel syndrome by treatments with calcium polycarbophil. Hepato-Gastroenterology. 2005;52:1416–20.PubMedGoogle Scholar
  44. 44.
    Catto-Smith AG, Coffey CM, Nolan TM, et al. Fecal incontinence after the surgical treatment of Hirschsprung disease. J Pediatr. 1995;127:954–7.CrossRefPubMedGoogle Scholar
  45. 45.
    Teitelbaum DH, Drongowski RA, Chamberlain JN, Coran AG. Long-term stooling patterns in infants undergoing primary endorectal pullthrough for Hirschsprung’s disease. J Pediatr Surg. 1997;32:1049–53.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  1. 1.Department of Pediatric SurgeryKurume University School of MedicineKurumeJapan

Personalised recommendations